Tina Cascone
MD Anderson Cancer Center Houston, TX 77030 · M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Tina Cascone as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:34 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05061550 · Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancerAstraZeneca · recruiting · Non-small Cell Lung Cancer · principal investigator
- Ph2NCT04560686 · Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung CancerM.D. Anderson Cancer Center · terminated · Resectable Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8 · principal investigator
- Ph2NCT03158129 · Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung CancerM.D. Anderson Cancer Center · completed · Stage I Lung Non-Small Cell Cancer AJCC v7, Stage IA Lung Non-Small Cell Carcinoma AJCC v7, Stage IB Lung Non-Small Cell Carcinoma AJCC v7 · principal investigator
- Ph1NCT02225405 · Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung CancerM.D. Anderson Cancer Center · completed · Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 · principal investigator
- Ph1NCT00254384 · Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following SurgeryM.D. Anderson Cancer Center · completed · Recurrent Lung Non-Small Cell Carcinoma, Stage IA Lung Non-Small Cell Carcinoma AJCC v7, Stage IB Lung Non-Small Cell Carcinoma AJCC v7 · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:34 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Dissecting the role of B lineage cells in mediating response of resectable lung cancer to neoadjuvant immune-based therapyR01CA287734 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2024 to 2026 · $677,143 awarded in 2026Same name and institution; not confirmed by an ID
- Radioimmunogenomic Habitat Phenotypes to Predict Efficacy of Neoadjuvant Immunotherapies in Non-Small Cell Lung CancerR01CA262425 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2021 to 2025 · $606,797 awarded in 2025Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name in non-small cell lung cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:34 UTC. The ranking covers the 200 most relevant of 17 PubMed records, and a shared surname and initials can bring in a namesake. All 17 on PubMed
- 567 citationsRCR 26.2
- Perioperative Nivolumab in Resectable Lung Cancer.N Engl J Med · 2024535 citationsRCR 59.3
- 217 citationsRCR 17.7
- 213 citationsRCR 14.3
- Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial.Cancer Discov · 2023131 citationsRCR 8.5
- Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity.Cancer Cell · 2022102 citationsRCR 5.8
- Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer.Nat Commun · 202195 citationsRCR 4.2
- Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer.J Thorac Cardiovasc Surg · 202280 citationsRCR 5.1
- 41 citationsRCR 6.5
- Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial.J Immunother Cancer · 202331 citationsRCR 2.5